文献速递造血干细胞移植与细胞治疗

使用携带者供者进行造血干细胞移植治疗CD40L缺陷可获得优异免疫功能和cTfh中更高的CD40L表达

HSCT using carrier donors for CD40L deficiency results in excellent immune function and higher CD40L expression in cTfh.
PubMed 文献 · Blood Adv · 2022-01-01

研究分析了7例CD40L缺陷携带者的免疫特征,其中4例作为供者为其CD40L缺陷家属行造血干细胞移植。携带者免疫球蛋白、CD4、CD8、cTfh及Treg与健康对照相当,CD40L表达为37%至78%;4例受者均植入成功,免疫重建优异,无机会性感染、移植物抗宿主病及免疫失调,移植后1至5年CD40L表达稳定,4例中3例实现免疫球蛋白独立。

要点

  • CD40L携带者免疫球蛋白、CD4、CD8、cTfh及Treg与健康对照相当,CD40L表达37%至78%。
  • 携带者cTfh细胞的CD40L表达高于总CD4细胞或记忆CD4细胞群。
  • 4例CD40L缺陷患者接受携带者供者HSCT均植入,免疫重建优异,无机会性感染、GVHD及免疫失调。

核心结论

  • 携带者cTfh细胞群CD40L表达更高,使用CD40L携带者作为供者为CD40L缺陷患者行HSCT可获得优异免疫重建。

研究设计与样本

  • 研究7例CD40L缺陷携带者的免疫特征,其中4例作为供者为其CD40L缺陷家属行HSCT,并分析移植结局。

主要发现

  • 携带者免疫球蛋白谱、CD4、CD8、cTfh细胞及Treg与健康对照相当,CD40L表达范围为37%至78%。
  • 携带者cTfh细胞的CD40L表达高于总CD4细胞或记忆CD4细胞群,Treg在携带者与健康对照中CD40L表达均极低。
  • 4例CD40L缺陷患者接受CD40L表达37%至63%的携带者供者HSCT,全部植入,免疫重建优异,无机会性感染、移植物抗宿主病及免疫失调。
  • 移植后1至5年CD40L表达稳定,与供者相似;4例中3例实现免疫球蛋白独立。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Data are limited regarding the immune status of CD40 ligand (CD40L)-deficient carriers and hematopoietic stem cell transplantation (HSCT) outcomes using them as donors for CD40L-deficient patients. Therefore, we studied the immune profiles of 7 carriers, 4 of whom were HSCT donors for family members with CD40L deficiency, and we characterized their HSCT outcomes. Immunoglobulin profiles, CD4, CD8, circulating T-follicular helper (cTfh) cells, and regulatory T cells (Tregs) in carriers were comparable to those in healthy controls. CD40L expression in carriers ranged from 37% to 78%. cTfh cells from carriers expressed higher CD40L compared with total CD4 cells or the memory CD4 compartment, suggesting a potential advantage to CD40L-expressing cTfh cells. Tregs had minimal CD40L expression in carriers and healthy controls. So we postulated that HSCT using donors who were CD40L carriers may result in excellent immune reconstitution without immune dysregulation. Four CD40L-deficient patients underwent HSCT from carriers who had CD40L expression from 37% to 63%. All patients engrafted, achieved excellent immune reconstitution with lack of opportunistic infections, graft-versus-host disease, and immune dysregulation; stable CD40L expression mimicked that of donors 1 to 5 years after HSCT. Immunoglobulin independence was achieved in 3 of the 4 patients. We demonstrated higher CD40L expression in the cTfh compartment of carriers and excellent immune reconstitution using donors who were CD40L carriers in CD40L-deficient patients.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Chandrakasan S, Chandra S, Prince C, et al. HSCT using carrier donors for CD40L deficiency results in excellent immune function and higher CD40L expression in cTfh. Blood Adv. 2022. PMID: 35443026. doi:10.1182/bloodadvances.2021006905

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。